Santen Pharmaceutical Co., Ltd.
https://www.santen.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Santen Pharmaceutical Co., Ltd.
Finance Watch: Big Bucks For T-regs In Autoimmune Diseases, Inflammation
GentiBio closed a $157m series A venture capital round, while clinical trial innovator Reify Health raised a $220m series C and Neurelis secured $150m. Also, IPOs slowed in August, but Adagio and Eliem grossed $309.4m and $80m, respectively, and RNA firm Greenlight will go public in a $282m SPAC deal.
Finance Watch: A Summer Slowdown? Not For Venture Capital Mega-Rounds
Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.
T-knife Taps Into Investor Interest in T-Cell Receptor Therapies
The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.
Digital Health Roundup, June 2021: Winners In Record-Breaking H1 Digital Health Funding; ADA 2021; Telehealth Update
In this roundup feature focusing on the developments in digital health, we highlight the key news and announcements from June.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Eyevance Pharmaceuticals LLC.
- Novagali Pharma SA
- Santen Inc.
- Chongqing Santen Kerui Pharmaceutical Co., Ltd
- InnFocus Inc,